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ABSTRACT
Adrenal hypoplasia congenita (AHC) is an X-linked disorder
caused by mutations in a gene referred to as DAX-1. AHC is char-
acterized by adrenal insufficiency and failure to undergo puberty
because of hypogonadotropic hypogonadism. The DAX-1 protein is
structurally related to orphan nuclear receptors, although it lacks the
characteristic zinc finger DNA-binding domain that is highly con-
served in other members of this family. In this report, we describe the
clinical features and genetic alterations in six families with AHC.
These patients reveal the variable clinical presentation of adrenal
insufficiency in AHC and underscore the importance of considering
this diagnosis. Nonsense mutations that introduce a stop codon were
found in three cases (W171X, W171X, Y399X). Frameshift mutations
(405delT, 501delA, and 702delC), each of which resulted in a prema-
ture stop codon at amino acid 263, were found in the other three
families. Three of these mutations (Y399X, 405delT, 702delC) are
novel. Using transient gene expression assays to assess DAX-1 func-
tion, these mutations were shown to eliminate the ability of DAX-1 to
repress the transcription of genes that are stimulated by a related
nuclear receptor, steroidogenic factor-1. These studies reveal the vari-
able clinical presentation of DAX-1 mutations and emphasize the
value of genetic testing in boys with primary adrenal insufficiency and
suspected X-linked AHC. (J Clin Endocrin Metab 84: 504–511, 1999)
ADRENAL hypoplasia congenita (AHC) is a rare inher-ited disorder that occurs in two distinct forms: X-
linked and autosomal recessive (1, 2). In X-linked AHC,
primary adrenocortical failure occurs because the adrenal
glands lack the permanent adult cortical zone. The remaining
cells are termed “cytomegalic” because they are larger than
typical fetal adrenal cells and contain characteristic nuclear
inclusions from cytoplasmic invaginations (3). Patients with
X-linked AHC frequently develop severe salt-wasting with
glucocorticoid and mineralocorticoid insufficiency in in-
fancy (4). The disorder is lethal unless appropriate steroid
hormone replacement is provided. Hypogonadotropic hy-
pogonadism is also commonly associated with X-linked
AHC (5). It is usually detected because of the absence of
pubertal development, and gonadotropin deficiency is
caused by abnormalities in both hypothalamic and pituitary
control of gonadotropin secretion (6).
The genetic locus for X-linked AHC was mapped to Xp21
through studies of male patients with contiguous gene de-
letion syndromes (glycerol kinase deficiency, Duchenne
muscular dystrophy, ornithine transcarbamylase deficiency,
and mental retardation) (7–9). This region of the X chromo-
some is also the location of the dosage-sensitive sex reversal
(DSS) locus important in sex determination (10, 11). In 1994,
the human DAX-1 (DSS–AHC critical region on the X chro-
mosome, gene 1) gene was cloned and mutations in DAX-1
were identified as causing both AHC and the associated
hypogonadotropic hypogonadism (12, 13). This gene en-
codes a 470 amino acid protein, with approximately 50%
homology between the carboxy-terminal region of DAX-1
and the ligand-binding domain (E domain) of the nuclear
hormone receptor superfamily (12, 14, 15). DAX-1 is classi-
fied as an orphan nuclear receptor because no specific ligand
has been identified to date (16). However, unlike other mem-
bers of this family, DAX-1 lacks a typical zinc-finger DNA-
binding domain. The unique amino-terminal portion of
DAX-1 contains 31⁄2 repeats of a 65–67 amino acid motif (12)
that may bind to hairpin loop structures in DNA (17).
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DAX-1 plays a key role in the development of the adrenal
gland and the hypothalamo-pituitary-gonadal axis. It is ex-
pressed in the developing urogenital ridge, ovary, testis,
adrenal cortex, hypothalamus, and anterior pituitary gland
(18, 19), and it colocalizes with another nuclear receptor
protein, steroidogenic factor-1 (SF-1) (20). SF-1 regulates the
expression of steroidogenic enzymes (21–23). Targeted dis-
ruption of the gene in mice leads to complete adrenal and
gonadal agenesis, persistence of Mu¨llerian structures in male
mice (24), impaired expression of gonadotrope-specific
markers in the anterior pituitary (25), and disruption of the
hypothalamic ventromedial nucleus (26). Recently, in vitro
studies showed that DAX-1 and SF-1 bind to one another
through protein–protein interactions (27–29). DAX-1 has
been shown to repress SF-1-mediated transactivation (27–
30). A repression domain has been localized to the carboxy-
terminus of DAX-1 (17, 27), a region that is deleted in many
patients with AHC. In this report, we describe the clinical
features and genetic analyses in six racially and geograph-
ically diverse families with DAX-1 mutations who had early-
and late-onset adrenal insufficiency. The functional effects of
these mutations were examined using transient expression
assays of SF-1-mediated transcription.
Materials and Methods
PCR and direct sequencing of DAX-1 gene
After obtaining Institutional Review Board approval and informed
consent from patients and family members, DNA was extracted from
blood leukocytes. The 3 kb DAX-1 intron was amplified by PCR using
a GeneAmp XL kit (Perkin Elmer, Foster City, CA) to allow the design
of intronic oligonucleotide primers. Exons 1 and 2 of the DAX-1 gene
were amplified from genomic DNA using the M13-tagged primers
shown below (M13 sequence is not shown):
DAX 1.1 For: 59-GCT CCC ACG CTG CTG TTC TTC-39
DAX 1.1 Rev: 59-CCG CCC ACC CGG AAG CCC CGC-39
DAX 1.2 For: 59-CGA AGG CGC CCG AGG CGA CGC-39
DAX 1.2 Rev: 59-GGA CGC CCA GCA GTT GCG CAC-39
DAX 1.3 For: 59-CGC TTC GTC AAG TAC TTG CCC-39
DAX 1 Splice Rev: 59-GTG TAG AGA GCC AAG TAC-39
DAX 2 Splice For: 59-TCC ACA CGT GTG CAT AGA AAC-39
DAX 2 Splice Rev: 59-TGT ACA GAG CTA TGC TAC CTG-39
PCR was performed in a 100-mL reaction containing 100 ng genomic
DNA, 50 pmol primers, 50 mM dNTPs, 1.1 mM MgCl2, and 5 U Taq
polymerase (Promega, Madison, WI) in a buffer containing 10 mM
Tris-HCl (pH 9.0), 50 mM KCl, 5% dimethylsulfoxide, and 0.1% Triton
X-100. PCR conditions were 1 min predenaturation at 96 C, nine cycles
of 1 min at 94 C, annealing for 1 min at 60 C, extension for 1 min at 72
C, 26 cycles of 1 min at 94 C, annealing (55–57.5 C) for 1 min, extension
for 1 min at 72 C, and 15 min elongation at 72 C. Direct DNA sequencing
was performed with Dye Primer Cycle Sequencing kits (Perkin Elmer)
using an automated sequencer (Applied Biosystems Model 373A DNA
Sequencer, Foster City, CA). For each exon, products from three different
PCR reactions were sequenced in both directions. Sequences obtained
from members of each kindred were compared with those from two
unrelated normal control subjects. In potential heterozygotes, results of
direct DNA sequencing were confirmed by subcloning purified PCR
products into the pCR II vector (TA cloning kit, Invitrogen, San Diego,
CA), and Taq cycle sequencing was performed on both strands as de-
scribed above. At least eight subclones were sequenced.
Plasmid construction and transient expression assays
Eukaryotic expression vectors for the DAX-1 mutants were con-
structed from the pBKCMV (-lacZ promoter) human DAX-1 cDNA vec-
tor as described previously (27). The mutations were created by the
overlapping PCR technique using primers containing the appropriate
nucleotide substitutions. PCR-amplified mutant fragments were di-
gested with restriction enzymes and inserted into the wild-type cDNA
sequence. Construction of the expression vector for the GAL4-SF-1 fu-
sion protein and the reporter construct UAS-TK109luc has been de-
scribed (27).
Human choriocarcinoma JEG-3 cells (American Type Culture Col-
lection HTB 36) were maintained in DMEM supplemented with 10%
fetal bovine serum and 1% penicillin and streptomycin in a 5% CO2
atmosphere at 37 C. Cells were transfected with 500 ng UAS-TK109luc,
50 ng pSG424-GAL4 or GAL4-SF-1, and 20 ng pBKCMV expression
vector (empty vector, DAX-1 wild type or DAX-1 mutant) using calcium
phosphate precipitation as described previously (27). Each individual
transfection reaction was performed in triplicate. Cell extracts were
prepared 24 h after transfection, and luciferase assays were performed.
The mean luciferase activity of each triplicate reaction was expressed as
a percentage of GAL4-SF-1 to allow comparison of data from different
experiments. The results represent the mean 6 sem from four different
experiments, each consisting of triplicate transfections.
Results
Case reports
Individuals from six families with suspected X-linked
AHC were studied. The pedigrees of four families are shown
in Fig. 1. Clinical details of individual presentations are sum-
marized in Table 1, and investigations of adrenal and go-
nadal function are shown in Tables 1 and 2, respectively.
The majority of our patients presented in the neonatal period
with salt-losing states and adrenal insufficiency. Patient RG
(III-1) is of Irish Caucasian origin. He developed progressive
failure to thrive, vomiting and dehydration, and had biochem-
ical evidence of hyponatremia and hyperkalemia.
Half-brothers in kindred DK (III-1, III-3) were of American
Caucasian origin and had a similar early clinical presenta-
tion. In patient DK:III-1, a diagnosis of 21-hydroxylase de-
ficiency was made initially but was revised when he failed
to enter puberty. His brother (DK:III-3) had normal electro-
lytes and cortisol at birth but developed hyperkalemia at 1
week of age.
Both BK brothers (IV-2, IV-3) presented in the first 2 weeks
of life. They were also from an American Caucasian family.
BK:IV-2 presented in a salt-losing crisis at 2 weeks of age but
responded well to steroid replacement. His younger brother
(IV-3) had normal electrolytes and cortisol (30 mg/dl) 24 h
after birth but presented 2 weeks later with meningitis, sei-
zures, and a salt-losing crisis. Of note, an older brother (IV-1)
had died of congenital adrenal insufficiency and had hyp-
oplastic adrenal glands at autopsy. Two maternal uncles
(III-3, III-4) died in the first 2 days of life and had similar
findings, and a cousin of their mother (III-1) was diagnosed
with Addison’s disease at the age of 7 yr. BK:IV-2 failed to
develop puberty. He showed little response to GnRH stim-
ulation and remains on testosterone replacement (Table 2).
BK:IV-3 has severe learning difficulties after a head injury in
childhood, and no formal investigations have been per-
formed; at 24 yr of age he remains prepubertal.
Kindred LS are of Mexican descent and were older at the
time of diagnosis. The eldest son (IV-1) presented at the age
of 2.5 yr with vomiting, dehydration, and shock, and a di-
agnosis of primary adrenal insufficiency was made. Cortisol
was undetectable and ACTH was elevated. His maternal
uncle (III-2) had been given a diagnosis of Addison’s disease
when 2 yr old, and his great uncle (II-1) had died unexpect-
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edly at 2 months of age from gastroenteritis. When his
younger brother (IV-2) became hyperpigmented at 1 yr of
age, the diagnosis of adrenal insufficiency was made, al-
though he was otherwise asymptomatic at the time.
Patient LP was born in Scotland. He was diagnosed with
craniosynostosis and developed cyanosis while under sedation
for a cranial computed tomographic scan. He had repeated
vomiting, cyanotic episodes, and epileptic seizures thereafter,
but improved with glucocorticoid, mineralocorticoid, and salt
replacement and underwent corrective surgery uneventfully.
SS, the eldest son in a family of Asian Indian descent, also
had a delayed presentation. He was diagnosed with adrenal
insufficiency at the age of 7 yr after a hypotensive episode
and hyponatremia during an acute asthma attack. Peak cor-
tisol response to ACTH stimulation was 3.2 ng/dl, and he
was started on glucocorticoid and mineralocorticoid replace-
ment. Although hyponatremia had been noted during an
episode of Escherichia coli septicemia at 6 days of age, he had
been well in early childhood but had developed progressive
malaise before presentation. He improved on treatment but
grew poorly and was reinvestigated at the age of 10 yr.
Steroid replacement was temporarily withdrawn, and pri-
mary adrenal insufficiency was confirmed (Table 1). On ste-
roid replacement, an unprimed insulin tolerance test pro-
duced a suboptimal peak GH response of 5.1 mU/L (1 ng/
ml 5 2.6 mU/L) (Hybritech Tandem-R, Liege, Belgium), and
growth hormone treatment was started. However, his failure
to enter puberty led to the diagnosis of X-linked AHC. He
was shown to have a poor gonadotropin response to GnRH
and a moderate testosterone response to three doses of hCG
(Table 2). Virilization was induced with testosterone, and
reevaluation at 18 yr of age confirmed hypogonadotropic
hypogonadism and revealed a borderline GH response to
stimulation (11.8 mU/L). At the age of 22 yr, he reached a
predicted height of 170.6 cm and remains on testosterone
replacement.
Mutational analyses
The DAX-1 gene was sequenced in each of the probands
and in available family members. The sequence findings are
summarized in Table 1. Nonsense mutations that introduce
a stop codon were found in three cases, and frameshift mu-
tations were found in three cases. These mutations, along
with others reported in the literature, are summarized in Fig.
2. The recommendations of Antonarakis (31) were adopted
to provide a consistent approach to nucleotide numbering,
because the designation of DAX-1 mutations differs in var-
FIG. 1. The pedigrees of four kindreds
with X-linked AHC. Hemizygous af-
fected males are indicated by filled
squares, and heterozygous carrier fe-
males are designated by a circle filled
with a dot. Carrier status was deter-
mined by direct sequencing or, in the
case of kindred DK, by restriction frag-
ment analysis. This was performed in
all numbered individuals still alive,
other than BK:III-1. Patient SS was
likely to have a de novo mutation after
investigation of his nuclear family. The
family members of patient LP have not
yet been studied.
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ious original reports. In this system, the A of the ATG trans-
lational initiation codon is designated as nucleotide 11.
In SS, three nucleotide changes were present in exon 1.
Two of these resulted in silent polymorphisms: cysteine at
codon 38 was encoded by TGC rather than TGT (change at
nucleotide 114), and CGA replaced CGG encoding arginine
at codon 166 (change at nucleotide 498). The latter substitu-
tion was also found in the patient’s father. The third change
caused a mutation in DAX-1. A TGG3 TAG conversion at
nucleotide 512 resulted in a premature stop codon at codon
171 in place of tryptophan. This mutation was not found in
the patient’s mother or brother, suggesting that she was not
a carrier, and that it may have arisen de novo in the affected
patient. However, the demonstration of gonadal mosaicism
for this disease by Zhang et al. (32) indicates that females who
are shown not to be carriers for DAX-1 mutations are po-
tentially at risk of having affected sons, and such families
should be counseled appropriately. In the DK kindred, a
nonsense mutation was also found in codon 171. However,
in this case, the substitution was TGG3 TGA at nucleotide
513. This eliminated an Xcm I site and allowed the screening
of additional family members by restriction enzyme analysis.
The proband’s mother (II-2), grandmother (I-1), and a ma-
ternal aunt (II-1) were found to be carriers (Fig. 1).
In LP, a nucleotide transversion at position 1197 (C3 A)
resulted in a novel mutation, introducing a stop codon at
TABLE 1. Clinical features and age at diagnosis of boys with DAX-1 mutations
Mutation Kindred Patient Age atdiagnosis Mode of presentation
Cortisol
(mg/dl)
ACTH
(pg/ml)
Nonsense
W171X SS de novo 7 yr Hyperpigmentation; progressive
malaise; hypotensive during an
asthma attack, hyponatremic with
sepsis, at age 6 days
3.2a/1.0b 1100b
W171X DK III-1 2 weeks Salt-wasting crisis; pubertal failure
suggested X-linked AHC
III-3 1 week Salt-wasting crisis 3.2c 253d
Y399X LPe 6 weeks Craniosynostosis diagnosed at birth;
collapsed under sedation for a cranial
CT scan; repeated vomiting, cyanotic
episodes, and seizures ensued
0.6 3587
Frameshift
405delT; codon 135
(stop codon 263)
RG III-1 2 weeks Poor feeding; poor weight gain;
dehydration
2.4
501delA; codon 167
(stop codon 263)
BKf IV-2 2 weeks Salt-wasting crisis 10.7g/,2.0h
IV-3 2 weeks Salt-wasting crisis; meningitis and
seizures
30.6i
702delC; codon 233/4
(stop codon 263)
LSj III-2 2 yr Progressive malaise; shock ,1.0k 937
IV-1 2.5 yr Vomiting; dehydration; shock 2.0k 640
IV-2 1 yr Hyperpigmented; asymptomatic 3.8k 802
a Peak cortisol response to standard synacthen test: 3.2 mg/dl.
b Age 10 yr; peak cortisol response to prolonged synacthen test: 1.4 mg/dl (day 3) (off hydrocortisone treatment).
c Peak cortisol response to standard synacthen test: 18 mg/dl (basal) to 28 mg/dl (peak).
d ACTH concentration age 19 days on glucocorticoid and mineralocorticoid replacement.
e Kindred LP: other family members have not been screened for DAX-1 mutations.
f Kindred BK: eldest brother (IV-1) and two maternal uncles (III-3 and III-4) died in the first week of life from “congenital adrenal insufficiency”
with hypoplastic adrenal glands; mother’s cousin (III-1) diagnosed as having Addison’s disease.
g Subnormal 17-ketosteroids, even after ACTH stimulation.
h Steroid replacement started once cortisol concentrations had declined.
i Presented 2 weeks later with meningitis, seizures, and a salt-losing crisis.
j Kindred LS: great uncle (II-1) died from gastroenteritis at 2 months of age.
k Measurements at various ages, reflecting the variable compliance with treatment in this family.
TABLE 2. Investigations of gonadal function in boys (.14 yr)
with DAX-1 mutations
Mutation Patient Age(yr)
Basal/PeakLHRH
Basal/post-
hCG
LH (IU/L) FSH
(IU/L)
Testosterone
(ng/dl)
Nonsense
W171X SS 10.8 1.9 2.4 0.9 1.3
16.8 ,1.0 1.6 1.3 1.3 ,23 310
18.7 ,1.0 ,1.0 1.4 1.5
W171X DK: III-1 14.0 11.7 4.4 7
15.1 ,0.5 ,0.5 0.6 0.9 u/d
Frameshift
501delA BK: IV-2 15.7a 7.3 8.1 1.4 3.1
18.8b 10.3 13.6 3.0 3.5 3
19.6c ,3.0 ,3.0 2.4 4.6 ,10
19.7c ,3.0 8.8 ,2.0 ,2.0 ,10
19.9c ,3.0 8.2 ,2.0 3.9
BK:IV-3d
u/d, Undetectable.
a BK: IV-2 had received six monthly injections of testosterone en-
anthate (200 mg im) before this test.
b Off testosterone (100 mg im monthly) for 2 months.
c LHRH tests performed at the start of and during 8 months treat-
ment with leuprolide, 1 mg/kg sc qd. His testicular volume increased
from 2.5 to 2.9 cm.
d BK: IV-3 has severe learning difficulties after a head injury at age
3 yr. He has not had any tests of gonadal function and remains Tanner
stage 1 at 24 yr of age.
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amino acid 399 within the putative ligand-binding domain of
DAX-1. Other family members were not available for
screening.
RG had a novel deletion of thymidine at nucleotide 405,
causing a frameshift and premature stop codon at amino acid
263. His mother was heterozygous for this mutation, and a
maternal aunt, pregnant at the time of the study, was also
found to be a carrier of the mutation. His father was hemi-
zygous and his mother heterozygous for the T 3 C poly-
morphism at nucleotide 114.
In the BK kindred, a deletion of adenosine at nucleotide
501 resulted in a frameshift and premature stop codon at
amino acid 263. Affected males (IV-2, IV-3) were hemizygous
for this deletion, and carrier females (II-1, III-5) were het-
erozygous. A cousin of their mother (III-2), pregnant at the
time of the study, was not a carrier of this mutation. She gave
birth to a healthy baby boy. Silent polymorphisms were
found in one brother (IV-3, G3 A at nucleotide 498) and in
his mother (III-5, T 3 C at nucleotide 114).
In the LS kindred, all three affected males (III-2, IV-1, IV-2)
were hemizygous for a previously unreported deletion of
cytosine at nucleotide 702, causing a frameshift and prema-
ture stop codon, again at amino acid 263. As predicted from
X-linked inheritance, both the mother and grandmother were
FIG. 2. Summary of naturally occurring DAX-1 mutations. The locations of DAX-1 mutations are depicted relative to their domain structure.
The nuclear receptor-like domain is shaded, and the aminoterminal repeats are depicted by arrows. The junction of exons 1 and 2 is denoted
by an arrowhead. The black bar represents the reported transcriptional silencing domain (17). Because the numbering system and designation
of mutations differ in various original reports, all mutations are indicated as described below (31). The A of the ATG translational initiation
codon is designated nucleotide 11. The locations of frameshift mutations are shown at the position of the actual mutation rather than at the
location of the resultant premature stop codon. For mutations that occur within nucleotide repeats, the mutation (either insertion or deletion)
is depicted as the 39-most nucleotide within the repeat. Frameshift and nonsense mutations that lead to premature truncation of the protein
are shown in the top two panels. Nucleotide insertions or deletions are illustrated in the top figure, and the locations of mutations that create
stop codons are shown in the middle figure. Missense mutations and the single codon deletion (delV269) are shown in the bottom panel. Mutations
described in this report are shown in bold below the schematic diagrams. Note the broad distribution of mutations and the relatively high
frequency of frameshift and nonsense mutations (data derived from this report and mutations reported in references 6, 12–14, 32, 34–42, 49).
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heterozygous for this frameshift deletion, but it was not
found in the unaffected baby boy (IV-3). Two silent poly-
morphisms were also detected in this kindred; a T 3 C
transversion at nucleotide 114 was identified in all members,
and III-1 and II-2 were homozygous for this polymorphism.
A G 3 A transversion at nucleotide 498 was present in all
members apart from the unaffected baby. The mother and
grandmother were heterozygous for this polymorphism.
Function of DAX-1 mutations
DAX-1 has been shown to inhibit the transcription of re-
porter genes that are driven by SF-1 (17, 27–29). Therefore, we
tested whether the mutations in these patients altered this
property of DAX-1 (Fig. 3). The W171X (kindreds SS and DK),
Y399X (kindred LP), and 702delC (patient LS, truncation at
codon 263) mutations were inserted into a DAX-1 expression
plasmid. GAL4-SF-1-driven expression of the UAS-TKLuc
reporter gene was used to assay for SF-1-mediated transac-
tivation. GAL4-SF-1 alone stimulated the reporter gene 18-
fold when compared with the GAL4 DNA-binding domain
construct. Coexpression of wild-type DAX-1 greatly re-
pressed SF-1 activity (relative luciferase activity, 6%). This
inhibition was markedly reduced with each of the DAX-1
mutant vectors tested (W171X, 44%; 702delC, 90%; Y399X,
132%).
Discussion
In this study, we describe the clinical features and func-
tional effects of DAX-1 mutations in nine patients from six
families with adrenal hypoplasia congenita. In keeping with
other reports, disparity in the age of diagnosis was seen.
Several boys presented in neonatal life with salt-losing states,
whereas others had a more insidious presentation with ad-
renal failure later in childhood.
The clinical diagnosis of AHC is not always easily recog-
nized. Boys who present in the neonatal period with salt-
wasting and adrenal insufficiency are sometimes misdiag-
nosed with the more common disorder, 21-hydroxylase
deficiency (congenital adrenal hyperplasia), although the ad-
renal steroid profiles of these conditions are quite different.
In AHC, 17-hydroxyprogesterone levels are low, whereas
they are increased in congenital adrenal hyperplasia. Dis-
tinguishing these two disorders is important because they
differ in their clinical course, steroid management, and ge-
netic counseling. The recessive form of AHC should also be
considered as a cause of primary adrenal insufficiency in
infancy. It has a distinct miniature adult adrenal morphol-
ogy, characterized by small glands with a permanent cortical
zone but a diminished fetal zone (2). The genetic basis of the
recessive form of AHC is unknown. Finally, adrenal gland
hypoplasia may also occur in neonates with congenital de-
fects of the hypothalamus or pituitary, leading to ACTH
deficiency. This can be differentiated from the primary ad-
renal failure seen in X-linked AHC by relevant measure-
ments of electrolytes, mineralocorticoids, glucocorticoids,
and ACTH, and by the phenotypic features (e.g. anenceph-
aly) present in a subset of these children.
Some of our patients who presented in childhood were
diagnosed with Addison’s disease. However, the failure to
enter puberty, and the family history of adrenal insuffi-
ciency, prompted reconsideration of the initial diagnosis and
genetic investigation for X-linked AHC. In fact, when a
strong family history suggests X-linked adrenal insuffi-
ciency, adrenoleukodystrophy should also be excluded, be-
cause it can occasionally occur as adrenal insufficiency with-
out associated neurological features (33). Serum very long-
chain fatty acids will be elevated in adrenoleukodystrophy
but normal in AHC.
FIG. 3. Effect of DAX-1 mutations on
SF-1-mediated transcription. A sche-
matic depiction of the format of the
transcription assay is shown at the top.
Transcription by GAL4-SF-1 is blocked
by DAX-1. The GAL4 reporter gene
UAS-TK109luc (500 ng) was trans-
fected into JEG-3 cells with GAL4-SF-1
(50 ng) and full-length DAX-1 vector (20
ng) or with expression vectors for the
indicated DAX-1 mutants (20 ng).
Transfections were performed in tripli-
cate on four occasions. The relative lu-
ciferase activity was obtained by com-
paring the mean of each set of
triplicates with the luciferase response
of the GAL4-SF-1/pBKCMV empty vec-
tor in that study. The activity of the
GAL4 DNA-binding domain alone
(GAL4-DBD) and GAL4-SF-1 are
shown in the top two bars. The results
are the mean 6 SEM of four different
experiments, each consisting of tripli-
cate transfections.
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Variability in the presentation of patients with AHC raises
the issue of whether the type of DAX-1 mutation predicts the
severity of the disorder. That is, is there a relationship be-
tween genotype and phenotype? In the absence of detailed
or standardized biochemical and physiological data in many
cases, age at diagnosis remains the most accessible surrogate
marker for assessing the severity of adrenal dysfunction.
When the age of diagnosis of AHC is summarized for pa-
tients reported here and in other studies (6, 13, 14, 32, 34–42),
an apparent bimodal distribution emerges (Fig. 4). The ma-
jority of patients are diagnosed within the first 2 months of
life. Subsequently, few patients are diagnosed until later in
childhood, with similar numbers of patients presenting be-
tween the ages of 2 to 9 yr.
Based on the information available to date, there is no
obvious correlation between the type of mutation in DAX-1
and the age of presentation (13, 34). However, several factors
may confound this analysis. For example, symptoms may be
nonspecific and may be present for some time before the
diagnosis is made, particularly in childhood. Clinical pre-
sentation can be precipitated by environmental stresses (e.g.
infection, operative procedures) that may occur independent
of the degree of adrenal insufficiency. The diagnosis of AHC
is made sooner in boys with a previous family history of
X-linked adrenal failure in their brothers or uncles. Access to
medical care also varies in different regions of the world.
Finally, other genetic factors (modifier genes) may also in-
fluence the severity of adrenal failure. Studying individuals
within a single family may reduce some of these variables,
although disparate presentations of AHC within the same
kindred can be seen.
It is possible that the neonatal period is a particularly
vulnerable time for adrenal insufficiency because, in re-
ported cases, many boys present in severe salt-losing crises
at this time (Fig. 4). For those who do not, a more delayed and
insidious presentation in childhood seems to occur. There are
several factors that could explain this. The normal aldoste-
rone secretion rate, although fairly constant throughout life,
is much higher in infancy when related to body surface area
(43, 44). This finding suggests that there is normally a greater
requirement for mineralocorticoids in early life. Increased
mineralocorticoid requirements could reflect relatively low
sodium intake and limited access to fluids at this age, the
tendency to urinary sodium loss caused by higher concen-
trations of atrial natriuretic peptide (45), and the relative
insensitivity of the immature kidney to mineralocorticoid
action (46). Certain other clinical conditions associated with
salt loss (such as 21-hydroxylase deficiency and aldosterone
synthase deficiency) show an improvement in salt retention
as patients get older (46–48). Thus, if patients with AHC
survive the neonatal period, they may become less suscep-
tible to adrenal crisis until faced with severe illness or an-
other environmental stress later in life.
The DAX-1 mutations described in our study resulted in
abnormal DAX-1 proteins that either completely lacked or
had truncated ligand-binding domains. Most reported
DAX-1 mutations reported so far have arisen from gene
deletions or premature stop codons that cause a loss of the
carboxy-terminal region (6, 13, 14, 32, 34 –36, 38, 39, 41, 42,
49, 50). The exceptions include nine different missense
mutations (Fig. 2), located at amino acids 267 and 269 (13,
32), 291 (39), 300 (37), 377 (32), 382 (39), 385, 425 (32), and
440 (40). These missense mutations are particularly useful
for identifying important functional domains in DAX-1. In
a proposed three-dimensional model of DAX-1, residue
382 was suggested to maintain helix-to-helix contact
through a buried salt bridge (17). The location of a mis-
sense mutation in the extreme carboxy-terminus of DAX-1
(e.g. N440I) is consistent with the observation that various
mutations that truncate this region of DAX-1 are sufficient
to cause AHC.
Wild-type DAX-1 was shown recently to inhibit the tran-
scriptional effects of SF-1 (27). DAX-1 has also been shown
to suppress expression of the SF-1-regulated steroidogenic
acute regulatory protein promoter (17). Deletion of the car-
boxy-terminal end of DAX-1 reduces its ability to silence
gene expression (17, 27, 29). Therefore, AHC appears corre-
lated with loss of DAX-1 transcriptional repression by dis-
ruption of its silencing domain function. We used these fea-
tures of DAX-1 to test whether the W171X, 702delC, and
Y399X mutations reported here altered DAX-1 function. Each
one of these mutations was found to eliminate the ability of
DAX-1 to inhibit SF-1-mediated transcription. These types of
reporter gene assays may be useful to assess the functional
effects of DAX-1 mutations.
In summary, we identified six mutations in the DAX-1
gene causing AHC with a spectrum of clinical presentations.
Mutational analysis of the DAX-1 gene was useful for de-
finitive diagnosis of the patient as well as for genetic coun-
seling in families. These mutations were shown to eliminate
the ability of DAX-1 to inhibit SF-1-mediated transcription.
Animal models of Dax-1 mutations and overexpression (11),
in conjunction with longitudinal studies in humans, will be
useful to further define the functional role of DAX-1.
FIG. 4. Age at presentation of boys with DAX-1 mutations described
in the literature to date. The majority of patients presented in the first
2 months of life, or at various times after infancy. The patients de-
scribed in this report are included. Note the nonlinear division of the
age into weeks, months, and years (data derived from this study and
cases reported in references 6, 13, 14, 32, 34–42).
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